MoonLake Immunotherapeutics (MLTX) Stock: Price, Forecast & Analyst Target
MoonLake Immunotherapeutics (MLTX) — MoonshotScore 44/100 (Weak band), calculated Nov 18, 2026. Price $11.03 (+2.22%), as of the Nov 19, 2026 trading session; market cap $939M.
Educational signal · not a buy or sell recommendation · How to read this
MoonLake Immunotherapeutics · MLTX · NASDAQ
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. Their lead product, Sonelokimab, is currently in Phase II trials for multiple indications.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · MoonLake Immunotherapeutics (MLTX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, a strained balance sheet, stalling growth and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone. Business Quality: Thin; Financial Safety: Strained; Valuation: Rich; Growth Durability: Shrinking; Momentum: Quiet.
- EPS beat 2 of the last 8 reports
- Altman Z 1.22 · Piotroski F 2
- ROE -79.9% · ROA -50.6% · current ratio 9.13 · earnings yield -25.6% · free-cash-flow yield -22.9%
Holding back: weak fundamentals, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 46 | Fair | |
| 50 | Fair | |
| 45 | Fair | |
| 45 | Fair | |
| 44 | Weak | |
| 44 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $11.03 | |
| Change on the day | +2.22% | |
| 52-week range | $9.46 – $23.29 | |
| Market capitalisation | $939M | — |
| Shares traded on the day | 1.41M |
Price & events
Other perspectives
Council score for MoonLake Immunotherapeutics (MLTX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 12, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Oct 12, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Oct 12, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is MoonLake Immunotherapeutics (MLTX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. MoonLake Immunotherapeutics (MLTX) is listed on NASDAQ. It employs 130 people and is led by Jorge Santos da Silva. The market values it at $939M.
What do the latest results show for MoonLake Immunotherapeutics (MLTX)?
Short answer · as of
Against analyst estimates the company has EPS beat 2 of the last 8 reports.
What are the financial strengths and risks for MoonLake Immunotherapeutics (MLTX)?
Short answer · as of
What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 1.22 · Piotroski F 2. Trailing ratios: ROE -79.9% · ROA -50.6% · current ratio 9.13 · earnings yield -25.6% · free-cash-flow yield -22.9%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.22 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-79.9%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
What should you watch next at MoonLake Immunotherapeutics (MLTX)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $0.00 · EPS -3.57 · 0 analysts. Current published price targets run low $34.00 · high $50.00 · consensus $42.00 · median $42.00 against a quoted price of $11.03 (as of Nov 19, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for MLTX.
Checked against the records this page reads, on the dates shown above.
How does MoonLake Immunotherapeutics compare with its peers?
Short answer
MoonLake Immunotherapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $61.99 Nov 18, 2026 | $1.79B | 98 5-pillar Nov 18, 2026 | |
| $14.10 Nov 18, 2026 | $1.54B | 97 5-pillar Nov 18, 2026 | |
| $18.40 Nov 18, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $47.40 Nov 19, 2026 | $1.41B | 76 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $40.04 Nov 19, 2026 | $1.30B | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $14.22 Nov 19, 2026 | $4.99B | 67 5-pillar Nov 18, 2026 | |
| $18.52 Nov 19, 2026 | $1.14B | 66 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| MoonLake Immunotherapeutics (MLTX) — this page | $11.03 | $939M | 44 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $34.00 – $50.00
- Consensus target
- $42.00
- Median target
- $42.00
- Revenue estimate
- $0.00
- EPS estimate
- $-3.57
Consensus record · Captured .
Measured against a quoted price of $11.03 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 27, 2026
- Transactions
- 19
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 14
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MLTX in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0.13% | $5.78M | New position |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about MoonLake Immunotherapeutics (MLTX)?
MoonLake Immunotherapeutics Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the MLTX research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for MLTX?
MLTX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases.
Is MLTX a good stock to buy?
Stock Expert AI does not rate MLTX buy, sell or hold. MoonLake Immunotherapeutics carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MLTX stock price today?
The last price recorded for MoonLake Immunotherapeutics (MLTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MLTX price target?
The analyst consensus price target for MoonLake Immunotherapeutics (MLTX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about MLTX stock?
Analyst coverage of MoonLake Immunotherapeutics (MLTX) is focused on the potential of Sonelokimab and its ongoing Phase II clinical trials.
What are the key factors to evaluate for MLTX?
MoonLake Immunotherapeutics (MLTX) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Sonelokimab is in Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis. Not financial advice.
How frequently does MLTX data refresh on this page?
MLTX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MLTX's recent stock price performance?
MoonLake Immunotherapeutics (MLTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel Nanobody technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MLTX overvalued or undervalued right now?
MoonLake Immunotherapeutics (MLTX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 9 from Financial Modeling Prep (FMP), 10 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com